Filing Flows › Companies › BeOne Medicines › Timeline
BeOne Medicines stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+22.4% to $406.96
BeOne Medicines (ONC) stock rose 22% over the last 252 sessions, to $406.96. On the way it reported 5 quarters, its insiders filed 30 open-market trades and 18 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 6, 2026 | Form 144 | Form 144: Titus Benjamin Ball plans to sell $632K | +5.0% (+4.6% vs SPY) | — | — |
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 74.3% | +2.5% (+7.0% vs SPY) | — | — |
| Nov 5, 2026 | Form 144 | Form 144: Chan Lee plans to sell $421K | +2.5% (+7.0% vs SPY) | — | — |
| Sep 30, 2026 | Form 144 | Form 144: Chan Lee plans to sell $407K | +0.2% (+0.4% vs SPY) | −0.7% (−2.6% vs SPY) | +2.2% (+1.1% vs SPY) |
| Sep 8, 2026 | Form 144 | Form 144: Xiaodong Wang plans to sell $47.1M | −1.9% (−1.4% vs SPY) | −1.2% (0.0% vs SPY) | +1.2% (−0.2% vs SPY) |
| Sep 1, 2026 | Form 144 | Form 144: Titus Benjamin Ball plans to sell $47K | −0.3% (+0.4% vs SPY) | −2.3% (−2.1% vs SPY) | +1.7% (+2.1% vs SPY) |
| Sep 1, 2026 | Insider sale | Ball Titus B. sold $47K | −0.3% (+0.4% vs SPY) | −2.3% (−2.1% vs SPY) | +1.7% (+2.1% vs SPY) |
| Aug 25, 2026 | Form 144 | Form 144: Corazon D. Sanders plans to sell $788K | +1.2% (+0.8% vs SPY) | −3.4% (−3.8% vs SPY) | −1.9% (−2.7% vs SPY) |
| Aug 25, 2026 | Form 144 | Form 144: Xiaobin Wu plans to sell $5.6M | +1.2% (+0.8% vs SPY) | −3.4% (−3.8% vs SPY) | −1.9% (−2.7% vs SPY) |
| Aug 11, 2026 | Form 144 | Form 144: Chan Lee plans to sell $719K | +0.1% (+0.4% vs SPY) | +1.0% (+1.0% vs SPY) | −2.2% (−0.9% vs SPY) |
| Aug 10, 2026 | Form 144 | Form 144: John V Oyler plans to sell $83.9M | +3.0% (+3.1% vs SPY) | −0.2% (−0.6% vs SPY) | +0.9% (+1.9% vs SPY) |
| Aug 5, 2026 | Earnings | Earnings: beat the EPS estimate by 25.7% | +1.4% (+1.6% vs SPY) | +10.6% (+10.7% vs SPY) | +11.3% (+12.1% vs SPY) |
| Aug 3, 2026 | Form 144 | Form 144: Aaron Rosenberg plans to sell $362K | −0.7% (−2.1% vs SPY) | +9.7% (+6.3% vs SPY) | +12.9% (+10.3% vs SPY) |
| Aug 3, 2026 | Insider sale | Rosenberg Aaron sold $362K | −0.7% (−2.1% vs SPY) | +9.7% (+6.3% vs SPY) | +12.9% (+10.3% vs SPY) |
| Jul 30, 2026 | Form 144 | Form 144: Chan Lee plans to sell $338K | −1.6% (−3.2% vs SPY) | +0.1% (−5.3% vs SPY) | +13.0% (+7.4% vs SPY) |
| Jul 30, 2026 | Insider sale | Lee Chan Henry sold $338K | −1.6% (−3.2% vs SPY) | +0.1% (−5.3% vs SPY) | +13.0% (+7.4% vs SPY) |
| Jul 22, 2026 | Form 144 | Form 144: Chan Lee plans to sell $638K | +0.4% (+0.5% vs SPY) | +3.6% (+4.6% vs SPY) | +16.8% (+14.0% vs SPY) |
| Jul 14, 2026 | Form 144 | Form 144: John V Oyler plans to sell $156M | +0.9% (+0.5% vs SPY) | +2.2% (+3.1% vs SPY) | +16.7% (+13.9% vs SPY) |
| Jul 10, 2026 | Form 144 | Form 144: Pan-Oyler Foundation plans to sell $15.0M | −1.4% (−1.8% vs SPY) | +4.7% (+4.8% vs SPY) | +14.0% (+11.2% vs SPY) |
| Jul 10, 2026 | Form 144 | Form 144: John V Oyler plans to sell $45.4M | −1.4% (−1.8% vs SPY) | +4.7% (+4.8% vs SPY) | +14.0% (+11.2% vs SPY) |
| Jun 23, 2026 | Form 144 | Form 144: John Oyler plans to sell $934K | +1.6% (+3.0% vs SPY) | +6.5% (+7.0% vs SPY) | +16.3% (+15.9% vs SPY) |
| Jun 23, 2026 | Form 144 | Form 144: Xiaobin Wu plans to sell $357K | +1.6% (+3.0% vs SPY) | +6.5% (+7.0% vs SPY) | +16.3% (+15.9% vs SPY) |
| Jun 23, 2026 | Form 144 | Form 144: Lai Wang plans to sell $296K | +1.6% (+3.0% vs SPY) | +6.5% (+7.0% vs SPY) | +16.3% (+15.9% vs SPY) |
| Jun 23, 2026 | Insider sale | Wu Xiaobin sold $357K | +1.6% (+3.0% vs SPY) | +6.5% (+7.0% vs SPY) | +16.3% (+15.9% vs SPY) |
| Jun 23, 2026 | Insider sale | Wang Lai sold $296K | +1.6% (+3.0% vs SPY) | +6.5% (+7.0% vs SPY) | +16.3% (+15.9% vs SPY) |
| Jun 23, 2026 | Insider sale | Oyler John sold $934K | +1.6% (+3.0% vs SPY) | +6.5% (+7.0% vs SPY) | +16.3% (+15.9% vs SPY) |
| Jun 16, 2026 | Insider sale | Wu Xiaobin sold $362K | −1.6% (−1.0% vs SPY) | +2.9% (+5.5% vs SPY) | +16.8% (+17.2% vs SPY) |
| Jun 16, 2026 | Insider sale | Wang Lai sold $310K | −1.6% (−1.0% vs SPY) | +2.9% (+5.5% vs SPY) | +16.8% (+17.2% vs SPY) |
| Jun 16, 2026 | Insider sale | Oyler John sold $981K | −1.6% (−1.0% vs SPY) | +2.9% (+5.5% vs SPY) | +16.8% (+17.2% vs SPY) |
| Jun 16, 2026 | Insider sale | Lee Chan Henry sold $157K | −1.6% (−1.0% vs SPY) | +2.9% (+5.5% vs SPY) | +16.8% (+17.2% vs SPY) |
| Jun 11, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.6% (+1.1% vs SPY) | +3.7% (+2.3% vs SPY) | +16.4% (+14.2% vs SPY) |
| Jun 11, 2026 | Insider sale | Wu Xiaobin sold $164K | −1.3% (−3.0% vs SPY) | −0.4% (−2.5% vs SPY) | +14.2% (+10.8% vs SPY) |
| Jun 11, 2026 | Insider sale | Wang Lai sold $197K | −1.3% (−3.0% vs SPY) | −0.4% (−2.5% vs SPY) | +14.2% (+10.8% vs SPY) |
| Jun 11, 2026 | Insider sale | Rosenberg Aaron sold $163K | −1.3% (−3.0% vs SPY) | −0.4% (−2.5% vs SPY) | +14.2% (+10.8% vs SPY) |
| Jun 11, 2026 | Insider sale | Oyler John sold $501K | −1.3% (−3.0% vs SPY) | −0.4% (−2.5% vs SPY) | +14.2% (+10.8% vs SPY) |
| Jun 11, 2026 | Insider sale | Lee Chan Henry sold $110K | −1.3% (−3.0% vs SPY) | −0.4% (−2.5% vs SPY) | +14.2% (+10.8% vs SPY) |
| Jun 11, 2026 | Insider sale | Ball Titus B. sold $43K | −1.3% (−3.0% vs SPY) | −0.4% (−2.5% vs SPY) | +14.2% (+10.8% vs SPY) |
| Jun 8, 2026 | Insider sale | Wu Xiaobin sold $400K | +0.3% (0.0% vs SPY) | −2.1% (−2.7% vs SPY) | +11.1% (+9.8% vs SPY) |
| Jun 8, 2026 | Insider sale | Wang Lai sold $368K | +0.3% (0.0% vs SPY) | −2.1% (−2.7% vs SPY) | +11.1% (+9.8% vs SPY) |
| Jun 8, 2026 | Insider sale | Oyler John sold $1.3M | +0.3% (0.0% vs SPY) | −2.1% (−2.7% vs SPY) | +11.1% (+9.8% vs SPY) |
| Jun 8, 2026 | Insider sale | Lee Chan Henry sold $236K | +0.3% (0.0% vs SPY) | −2.1% (−2.7% vs SPY) | +11.1% (+9.8% vs SPY) |
| Jun 8, 2026 | Insider sale | Ball Titus B. sold $37K | +0.3% (0.0% vs SPY) | −2.1% (−2.7% vs SPY) | +11.1% (+9.8% vs SPY) |
| Jun 1, 2026 | Insider sale | Yi Qingqing sold $66K | −2.9% (−3.2% vs SPY) | −6.4% (−3.9% vs SPY) | −1.0% (0.0% vs SPY) |
| May 22, 2026 | Insider sale | Sanders Corazon (Corsee) D. sold $66K | +0.2% (−0.2% vs SPY) | −7.3% (−9.1% vs SPY) | −11.5% (−10.5% vs SPY) |
| May 22, 2026 | Insider sale | Riva Alessandro sold $66K | +0.2% (−0.2% vs SPY) | −7.3% (−9.1% vs SPY) | −11.5% (−10.5% vs SPY) |
| May 22, 2026 | Insider sale | Dugan Margaret sold $66K | +0.2% (−0.2% vs SPY) | −7.3% (−9.1% vs SPY) | −11.5% (−10.5% vs SPY) |
| May 22, 2026 | Insider sale | Baker Bros. Advisors LP sold $3.4M | +0.2% (−0.2% vs SPY) | −7.3% (−9.1% vs SPY) | −11.5% (−10.5% vs SPY) |
| May 6, 2026 | Earnings | Earnings: beat the EPS estimate by 143.3% | +5.2% (+3.8% vs SPY) | +5.7% (+3.8% vs SPY) | −6.1% (−10.6% vs SPY) |
| Feb 26, 2026 | Earnings | Earnings: missed the EPS estimate by -55.3% | −8.9% (−8.3% vs SPY) | −16.4% (−15.2% vs SPY) | −24.0% (−17.1% vs SPY) |
| Dec 19, 2025 | 8-K | Termination of a material agreement | +2.9% (+2.0% vs SPY) | +1.7% (−0.6% vs SPY) | +10.7% (+9.1% vs SPY) |
| Dec 18, 2025 | 8-K | Directors and officers: departures, appointments, pay | +0.3% (−0.4% vs SPY) | +1.8% (−1.2% vs SPY) | +8.8% (+7.6% vs SPY) |
| Nov 26, 2025 | Insider sale | Sanders Corazon (Corsee) D. sold $896K | +1.6% (+0.9% vs SPY) | +0.8% (−0.5% vs SPY) | −7.0% (−9.6% vs SPY) |
| Nov 19, 2025 | 8-K | Material definitive agreement | −2.8% (−3.2% vs SPY) | −8.2% (−10.5% vs SPY) | −17.0% (−19.4% vs SPY) |
| Nov 17, 2025 | Insider sale | Wu Xiaobin sold $1.5M | +2.9% (+3.8% vs SPY) | −5.1% (−3.1% vs SPY) | −18.4% (−19.4% vs SPY) |
| Nov 13, 2025 | Insider sale | Wu Xiaobin sold $2.3M | −2.4% (−0.8% vs SPY) | −6.5% (−3.4% vs SPY) | −16.8% (−16.6% vs SPY) |
| Nov 12, 2025 | Insider sale | Wu Xiaobin sold $3.6M | +9.4% (+9.3% vs SPY) | +5.7% (+9.2% vs SPY) | −6.8% (−7.7% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: beat the EPS estimate by 27.0% | +3.4% (+4.4% vs SPY) | +16.1% (+15.2% vs SPY) | +0.5% (−0.7% vs SPY) |
Insiders’ record here
In the year on the chart, BeOne Medicines' insiders reported 0 open-market buys ($0) and 30 sales ($19.6M). Of the 29 old enough to score, 4 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale +26.2%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.02 Termination of a material agreement | 2,368 | 0.0% | 51% | +1.1% | ±1.5% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → BeOne Medicines: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.